|
Sponsor
|
Studies ↑
|
Description
|
Ready to Share
|
Created
|
| |
|
GSK-102115
|
A dose-range study to assess the safety and immunogenicity of a novel HPV vaccine when administered intramuscularly according to a 3-dose schedule (0,1,6-month) in healthy adult females (18-25 years of age)
|
3/31/2014
|
| |
|
GSK-108052
|
A long-term, follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ novel HPV vaccine in healthy female subjects vaccinated in the primary study
|
3/31/2014
|
| |
|
GSK-107919
|
A dose-range study to assess the safety and immunogenicity of a novel HPV vaccine when administered intramuscularly according to a 3-dose schedule (0,1,6-month) in healthy adult females (18-25 years of age)
|
3/31/2014
|
| |
|
GSK-107921
|
A double-blind, controlled, randomised, phase II study of the safety and immunogenicity of an HPV-VLP vaccine against Human Papillomavirus Types 16, 18, 31 and 45 evaluated in Healthy Adult Female Volunteers in a 0, 1, 6 months schedule
|
4/1/2019
|
| |
|
GSK-107918
|
A double-blind, controlled, randomised, phase II study of the safety and immunogenicity of an HPV-VLP vaccine against Human Papillomavirus Types 16, 18, 31 and 45 evaluated in Healthy Adult Female Volunteers in a 0, 1, 6 months schedule
|
4/1/2019
|